From the first to the third generation adenoviral vector : What parameters are governing the production yield?

Download
  1. Get@NRC: From the first to the third generation adenoviral vector : What parameters are governing the production yield? (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1016/j.biotechadv.2008.10.003
AuthorSearch for: ; Search for: ; Search for:
TypeArticle
Journal titleBiotechnology Advances
Volume27
Issue2
Pages133144; # of pages: 12
SubjectAnimal; bio; Biotechnology; Cell Culture; Gene Therapy; Human; therapy; adenovirus; helper-dependent adenoviral vector; production; quantification
AbstractHuman adenoviral viral vector serotype 5 (AdV) is presently the primary viral vector used in gene therapy trials. Advancements in AdV process development directly contribute to the clinical application and commercialization of the AdV gene delivery technology. Notably, the development of AdV production in suspension culture has driven the increase in AdV volumetric and specific productivity, therefore providing large quantities of AdV required for clinical studies. This review focuses on detailing the viral, cell and cell culture parameters governing the productivity of the three generations of AdV vectors.
Publication date
LanguageEnglish
AffiliationNational Research Council Canada; NRC Biotechnology Research Institute
Peer reviewedNo
NRC number47833
NPARC number12390838
Export citationExport as RIS
Report a correctionReport a correction
Record identifiercbc7bc8a-f1be-4037-85a2-bf93bcc62815
Record created2009-10-26
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)